Olaparibis a prescription medicine used to treat adults with advanced or recurrent ovarian cancer, early or metastatic breast cancer, metastatic pancreatic cancer, and also metastatic prostate cancer.
This therapy acts on specific types of cancer cells with less harm to normal cells. Olaparib is a targeted therapy.
Two or more different medicines used at the same time to treat a patient.
No. Olaparib is not chemotherapy.
A treatment used after you have responded to initial therapy. It can help keep cancer from growing or returning. Olaparib can be used in certain people as maintenance therapy.
Olapari bworks by inhibiting PARP enzymes, preventing cancer cells with DNA repair defects (like BRCA mutations) from repairing themselves, leading to their death.
Olanib is a generic version of LYNPARZA which is Olaparib.
As a Least Developed Country (LDC), Bangladesh received a special waiver under the WTO’s TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) until 2033. This allows Bangladesh to produce generic versions of patented drugs without paying royalties, significantly reducing manufacturing costs.
No. As a commitment to patient affordability, Everest Pharmaceuticals Ltd. proudly introduces Olanib, the first global generic version of LYNPARZA (Olaparib). This medication is now accessible to patients worldwide at a more affordable price. Contact us to learn more about availability and purchasing options.
Yes,Olaparibhas common and serious side effects like Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), pneumonitis, venous thromboembolism, tiredness or weakness, low red blood cell counts, diarrhea, loss of appetite, headache. changes in the way food tastes, cough, low white blood cell counts, shortness of breath, dizziness, indigestion or heartburn, low platelet counts.
